ADMA - ADMA BIOLOGICS, INC.

16.38
-0.200   -1.221%

Share volume: 3,109,998
Last Updated: 03-03-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.31%

PREVIOUS CLOSE
CHG
CHG%
$16.58
-0.20
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
66%
Profitability 81%
Dept financing 26%
Liquidity 75%
Performance 60%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
5.20%
1 Month
-0.67%
3 Months
-18.55%
6 Months
-3.11%
1 Year
-3.70%
2 Year
186.36%
Key data
Stock price
$16.38
P/E Ratio 
0.00
DAY RANGE
$16.08 - $16.69
EPS 
$0.62
52 WEEK RANGE
$13.76 - $25.67
52 WEEK CHANGE
-$7.35
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-07-2025
BETA 
0.60
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$4,345,076
AVERAGE 30 VOLUME 
$2,850,559
Company detail
CEO: Adam S. Grossman
Region: US
Website: admabiologics.com
Employees: 530
IPO year: 2013
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

ADMA Biologics, Inc. engages in developing, manufacturing, and marketing specialty plasma-derived biologics. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI) and ASCENIV. Nabi-HB for the. treatment of acute exposure to blood containing Hepatitis B surface antigen.

Recent news